The U.S. Food and Drug Administration has extended the review period for GSK’s blood cancer drug Blenrep by three months, delaying its potential relaunch in the U.S. The continuation follows a withdrawal nearly three years ago. The company is continuing to pursue approval while navigating regulatory complexities. The delay adds to timing uncertainty in the multiple myeloma treatment landscape and reflects the FDA's cautious approach to new oncology therapies.